It is also theorized that a loss of upstream regulators such as MST1/2, LATS1/2, and NF2 and signaling pathways such as EGFR, PI4K/Akt, and RAS/RAF/MEK/ERK promote YAP/TAZ activity in cancer [162]. This evidence concerns the gene YAP1 and cancer.